Joblove v. Barr Labs, Inc.
| Decision Date | 25 June 2007 |
| Docket Number | No. 06–830.,06–830. |
| Parties | Betty JOBLOVE, et al., petitioners, v. BARR LABS, INC., et al. |
| Court | U.S. Supreme Court |
Case below, 466 F.3d 187.
Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
To continue reading
Request your trial
8 cases
-
In re Ciprofloxacin Hydrochloride Antitrust Lit.
...the parties settled" should be considered in the analysis, citing Brief for the United States as Amicus Curiae at *12, Joblove v. Barr Labs., ___ U.S. ___, 127 S.Ct. 3001, 168 L.Ed.2d 726 (2007) (No. 06-830), 2007 WL 1511527. According to the appellants, only the Second Circuit in In re Tam......
- In re K–Dur Antitrust Litig.
-
In re Actions
...Citrate Antitrust Litig., 466 F.3d 187, 201 n. 13 (2d Cir.2006), cert. denied sub. nom., Joblove v. Barr Labs, Inc., 551 U.S. 1144, 127 S.Ct. 3001, 168 L.Ed.2d 726 (2007) (“ Tamoxifen II”) (quoting State Oil Co. v. Khan, 522 U.S. 3, 10, 118 S.Ct. 275, 139 L.Ed.2d 199 (1997)). Generally, “th......
-
In re Lipitor Antitrust Litig.
...Citrate Antitrust Litig., 466 F.3d 187, 201 n. 13 (2d Cir.2006), cert. denied sub. nom., Joblove v. Barr Labs, Inc., 551 U.S. 1144, 127 S.Ct. 3001, 168 L.Ed.2d 726 (2007) (“Tamoxifen II”) (quoting State Oil Co. v. Khan, 522 U.S. 3, 10, 118 S.Ct. 275, 139 L.Ed.2d 199 (1997) ). Generally, “th......
Request a trial to view additional results
5 firm's commentaries
-
Clearance: Proskauer's Quarterly Antitrust Update - Winter 2013
...cert. denied, 126 S. Ct. 2929 (2006). See generally In re Tamoxifen Citrate Antitrust Litig., 466 F.3d 187 (2d Cir. 2006), cert. denied, 127 S. Ct. 3001 (2007); In re Ciprofloxacin Hydrochloride Antitrust Litig., 363 F. Supp. 2d 514, 526 (E.D.N.Y. 2005), aff'd, 544 F.3d 1323 (Fed. Cir. 2008......
-
U.S. Supreme Court To Weigh In On Reverse Payment Deals
...677 F.3d 1298; In re Tamoxifen Citrate Antitrust Litig., 429 F.3d 370 (2d Cir. 2005), amended, 466 F.3d 187 (2d Cir. 2006), cert. denied, 551 U.S. 1144 (2007); In re Ciprofloxacin Hydrochloride Antitrust Litig., 544 F.3d 1323 (Fed. Cir. 2008), cert. denied, 557 U.S. 920 (2009). In contrast,......
-
Supreme Court Rules On 'Reverse Payment' Settlements In Federal Trade Commission v. Actavis, Inc.
...F.3d at 1312; In re Tamoxifen Citrate Antitrust Litig., 429 F.3d 370 (2d Cir. 2005), amended, 466 F.3d 187 (2d Cir. 2006), cert. denied, 551 U.S. 1144 (2007); In re Ciprofloxacin Hydrochloride Antitrust Litig., 544 F.3d 1323 (Fed. Cir. 2008), cert. denied, 557 U.S. 920 (2009). The Court als......
-
Supreme Court Rules On 'Reverse Payment' Settlements In Federal Trade Commission v. Actavis, Inc.
...F.3d at 1312; In re Tamoxifen Citrate Antitrust Litig., 429 F.3d 370 (2d Cir. 2005), amended, 466 F.3d 187 (2d Cir. 2006), cert. denied, 551 U.S. 1144 (2007); In re Ciprofloxacin Hydrochloride Antitrust Litig., 544 F.3d 1323 (Fed. Cir. 2008), cert. denied, 557 U.S. 920 (2009). The Court als......
Request a trial to view additional results
3 books & journal articles
-
Settlement of Patent Litigation
...analysis. 29 25. 35 U.S.C. § 217(e)(2); In re Tamoxifen Citrate Antitrust Litig., 466 F.3d 187, 206 (2d Cir. 2006), cert. denied , 127 S. Ct. 3001 (2007) (generic company has not undertaken the “investment of substantial sums of money for manufacturing, marketing, legal fees and the like”).......
-
The Nexium Trial Pioneers Actavis' Activation: a Roundtable of Nexiums Counsel Reflect on Their Six-week Trial
...v. Bayer AG, 562 U.S. 1280 (2011); Ark. Carpenters Health & Welfare Fund v. Bayer AG, 557 U.S. 920 (2009); Joblove v. Barr Labs, Inc., 551 U.S. 1144 (2007); F.T.C. v. Schering-Plough Corp., 548 U.S. 919 (2006); Valley Drug Co. v. Geneva Pharms., Inc., 543 U.S. 939 (2004); and Andrx Pharms.,......
-
Generic entry in a rough economy - proposed legislation may ease health care costs.
...(149.) Id. at 211. (150.) Id. (151.) See Federal Trade Comm'n v. Schering-Plough Corp., 548 U.S. 919 (2006); Joblove v. Barr Labs, Inc., 551 U.S. 1144 (152.) Saul, supra note 26. (153.) Federal Trade Commission, FTC's Bureau of Competition Issues FY 2007 Summary of Pharmaceutical Company Se......